Search

Search Constraints

You searched for: Author/Creator Sureda, Anna

Search Results

1. A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma. Issue 1 (31st October 2022)

2. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper. Issue 10 (October 2022)

3. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Issue 2 (February 2019)

4. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T‐cell lymphoma, nasal type: a CIBMTR analysis. (2nd August 2017)

5. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Issue 8 (9th February 2018)

6. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. (17th December 2018)

7. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. (15th March 2016)

8. An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA. Issue 5 (27th May 2023)

9. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Issue 12 (12th April 2018)

10. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9980 (9th May 2015)